Treatment options for postmenopausal osteoporosis. by Singer, F
Treatment Options for 
Postmenopausal Osteoporosis 
Frank Singer MD 
Introduction 
Osteoporosis is a process or state of bone loss that results in 
increased risk for bone fractures. The most important sites of 
fracture are the spine and hip, although distal forearm and rib 
fractures are not uncommon. 
Sometimes 2 syndromes of osteoporosis are defined: Type I 
refers to postmenopausal osteoporosis, and Type II is senile 
osteoporosis. 1 Senile osteoporosis is the gradual process of bone 
loss that occurs as a result of aging in both women and men. 
Normally, bone is built up until peak bone mass is attained 
between the ages of 20 and 35, after which there is a slow 
progressive loss of bone.2 Hip fracture is the characteristic 
consequence of senile osteoporosis. 1 
Postmenopausal osteoporosis is a process that actually begins 
several years prior to the cessation of menstruation, ie, 
perimenopausally. The period of most rapid bone loss occurs 
during the first 5 years after menopause, with continued effects 
for approximately 3 to 5 years thereafter.2 Interestingly, men 
who become hypogonadal during adulthood also go through a 
period of accelerated bone loss that results in osteoporosis.3 
The process of postmenopausal osteoporosis probably affects 
all women to a variable degree. It has been proposed that there 
are fast losers and slow losers, but this concept has not been 
established. Bone mineral density can be measured safely and 
easily to determine a woman's fracture risk.4 However, rela-
tively high postmenopausal bone density might be a result of 
high peak bone mass and might not adequately reflect a person's 
rate of bone loss. 
There are several treatment options for postmenopausal 
osteoporosis: A variety of estrogen preparations, an oral 
bisphosphonate (etidronate), vitamin D, and calcitonin. Cal-
cium supplements should be a part of any treatment regimen; but 
in itself is not an adequate treatment.~-6 Calcium should be 
supplemented to achieve an intake of 1,500 mg a day; taking it 
with food improves absorption. It is important to read the label 
of a calcium supplement carefully to determine its elemental 
calcium content. 
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Estrogen Replacement Therapy 
The best-established prevention and treatment for postmeno-
pausal bone loss and fracture is estrogen replacement therapy 
(ERT)7 and estrogen is available in many forms. 
Historically, the most commonly used is conjugated estrogens 
(Premarin). The dose of conjugated estrogens usually recom-
mended for ERT is .625 mg daily,7 which provides full protec-
tion against postmenopausal osteoporosis.8This is a lower dos-
age than was commonly prescribed 10 or 20 years ago, but also 
may be higher than is necessary to treat osteoporosis. There are 
limited data to suggest that .3 mg of conjugated estrogens 
combined with 1,500 mg a day of supplemental calcium may 
produce an equivalent effect.9 An important reason to prefer the 
higher dose, however, is its advantage in improving cholesterol 
metabolism. 
Epidemiological data have strongly suggested that ERT is 
associated with reduced risk for coronary artery disease (CAD).10-
12 Approximately 70% of the women in these studies were using 
Premarin, which has been shown to lower LDL-cholesterol 
levels substantially when given in a daily dose of .625 mg; HDL-
cholesterollevels are increased slightly. Increasing the dose to 
1.25 mg produces little improvement in these results.13 There 
appears to be no data indicating that a dosage of .3 mg provides 
similar benefit. Since lowering LDL-cholesterollevels is known 
to reduce risk for coronary events, it is very likely that this is one 
mechanism through which ERT prevents CAD.13 
The dose response of other forms of estrogen has been studied 
in an attempt to determine the dosage required to attain full 
protection against postmenopausal osteoporosis. Piperazine 
estrone sulfate (Ogen) will provide full protection when given in 
a dose of 1.25 mg daily. A dosage of .625 mg also provides 
substantial benefit and was originally thought to be fully ad-
equate, 14 but longer term studies demonstrated that the higher 
dosage was necessary.15 The dose-response relationship be-
tween this form ofERT and lowering ofLDL-cholesterollevels 
has not been studied. 
Transdermal estradiol (Estraderm) is available for the preven-
tion of osteoporosis and is available in 2 doses: 50 meg and 100 
meg. Here again, the lower dose provides some protection, 
whereas the higher dose is fully adequate.16 Transdermal 
estroadiol has little effect on lipoprotein metabolism, 13 which is 
an obvious disadvantage, in general. Occasionally, transdermal 
estradiol may provide an advantage to women with 
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hypertriglyceridemia, in whom oral estrogen use may exacer-
bate this problem. Transdermal estradiol, unlike some oral 
estrogens, also does not raise levels of various liver proteins 
such as renin substrate. 17 
Oral micronized estradiol (Estrace) is available for ERT. Two 
mg of oral estradiol is equivalent to .625 mg of conjugated 
estrogens in its effect to lower LDL-cholesterollevels.U Oral 
estradiol in a daily dose of .5 mg to 2.0 mg provides protection 
against postmenopausal osteoporosis, but it is unclear which 
dosage is the minimum required to provide full protection. 18 
There are other estrogen preparations that are being marketed 
for ERT; for example, esterified estrogens. Little is known about 
appropriate dosing of esterified estrogens, although they are 
being used as a substitute for conjugated estrogens. These 2 
products are not equivalent in terms of their USP formulations: 
Conjugated estrogens have 35% equine estrogens; esterified 
estrogens have 10%.19 
Treatment Alternatives 
Why consider alternatives to ERT? There are several reasons. 
Estrogens are believed to be contraindicated in patients with a 
history of breast or endometrial cancer, and in patients with a 
history of thrombo-embolic disease.20 Oral estrogens probably 
should not be given to women who are at risk for severe 
hypertriglyceridemia. 
Postmenopausal estrogen use can result in menstrual bleed-
ing. When medroxyprogesterone acetate (Provera) is used to-
gether with estrogens in a cyclical fashion ( eg, 10 mg on days 15 
to 25 of the cycle) monthly withdrawal bleeding is to be 
expected. When lower doses of this progestagen ( eg, 2.5 mg to 
5.0 mg) are used concurrently with the estrogen throughout the 
month, bleeding is less frequent. 
Concurrent estrogen and progestagen use results in unwanted 
menstrual bleeding more often in women who begin ERT 
shortly after menopause than in women who are older. Some-
times, a lower dose of the estrogen and/or a higher dose of the 
progestagen may eliminate this problem. Nevertheless, for some 
women, menstrual bleeding remains an unacceptable side-effect 
ofERT. 
Some women develop breast tenderness when they start 
taking estrogens after menopause. This occurs more often at 
higher doses, but can occur in some women at relatively low 
doses. These women frequently discontinue ERT because of the 
discomfort. 
Some women fear the development of breast cancer as a 
consequence ofERT. Currently, the relationship between ERT 
and the risk of breast cancer is somewhat controversial. One 
meta-analysis arrived at a relative risk of 1.3 in association with 
ERT.21 It is unlikely that this meta-analysis underestimates the 
risk. Although the use of a progestagen eliminates the increased 
risk of endometrial cancer resulting from the use of estrogen 
alone, 22 the notion that the progestagen also attenuates the risk 
for breast cancer is without foundation. 
In responding to a patient's fear ofERT causing breast cancer, 
the physician is advised to try to determine whether this fear is 
deeply rooted and unshakeable or is open to influence. The 
epidemiological data strongly suggests that women who use 
ERT live longer than those who do not, with reduced risk for 
CAD.12•23 But not every patient is equally impressed. In particu-
lar, ERT may not be acceptable to a woman whose mother or 
sister had breast cancer. 
The alternatives to ERT include etidronate, vitamin D, and 
calcitonin. Among the 3, use of etidronate24-25 and vitamin 1)26 
have been shown to prevent loss of bone mineral density and 
occurence of fracture, whereas salmon calcitonin use has been 
associated with prevention of bone mineral density loss only.27 
Etidronate (Didronel) is given in a dose of 400 mg a day for 2 
weeks out of every 3 months.24-25 Calcium, magnesium, and a 
variety of foods interfere with its absorption, so it is best taken 
on an empty stomach at bedtime. The response to etidronate (and 
other alternative treatments) should be monitored after a year of 
therapy to be assured it is working. Ineffective treatment could 
be related to inadequate absorption. 
Vitamin D is another treatment that can be given orally. 
Although its efficacy is controversial, at least 1 study has 
demonstrated that calcitriol (Rocaltrol) taken in a dosage of .5 
meg daily preserves bone mineral density and prevents frac-
tures. 26 The risks of calcitriol are related to the possible develop-
ments of hypercalcemia and/or hypercalciuria. Therapy should 
be monitored and the dosage of calcitriol reduced if serum 
calcium exceeds the upper limit of normal or if 24-hour urinary 
calcium is excessive, ie, >250 mg to 300 mg. 
Calcitonin must be given parenterally and the initial dose 
should be low. Flushing and nausea commonly occur in the 
beginning, but often diminish or disappear with continued 
therapy. The dosage should be gradually increased to 100 IU of 
salmon calcitonin (Calcimar, Miacalcin) a day.27 Human calci-
tonin also is available, but the equivalency of dosing is uncer-
tain, the cost is higher, and it has no apparent clinical advantage. 
The best-established prevention and treatment for postmeno-
pausal osteoporosis is estrogen replacement therapy. Premarin 
has the advantage of being the estrogen most closely associated 
with the coronary-protective effects observed in epidemiologi-
cal studies and has a beneficial effect on the lipid profile in most 
women. However, other estrogen preparations, when used at 
appropriate dosages, provide equal protection against 
osteoporosis and also can be cardioprotective. For women who 
should not or wish not to use estrogen, currently available 
alternative treatments for osteoporosis include etidronate, vita-
min D, and calcitonin. Calcium supplementation to maintain a 
total intake of 1,500 mg a day also is generally advised. 
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Postpartum Preeclampsia Complicated 
by Acute Pulmonary Edema 
~ (Continued from Page 249) 
ing therapy with the agent, although reported cases of pulmo-
nary edema up to 72 hours after discontinuation of therapy have 
been reported. Our patient developed pulmonary edelila almost 
3 weeks after discontinuation of oral terbutaline, and it is 
unlikely that tocolytic therapy played a significant role in her 
presentation. 
Peripartum cardiomyopathy is another possible etiology in 
patients presenting with postpartum pulmonary edema. These 
patients typically present within 4 weeks antepartum and 5 
months postpartum.6 Alternatively, the contribution of this 
patient's previous treatment of Hodgkin's disease with chemo-
therapy and radiation therapy in her presentation is unclear. Both 
chemotherapeutic agents and mediastinal radiation therapy can 
cause myocardial toxicity leading to left ventricular dysfunc-
tion. 7•8 Our patient, however, had no evidence ofleft ventricular 
dilation or systolic dysfunction on echocardiograrn to suggest 
either peripartum cardiomyopathy or cardiomyopathy second-
ary to chemotherapy or radiation therapy. 
In summary, postpartum acute pulmonary edema is a rare but 
well-described complication of pregnancy. Multiple possible 
etiologies including peripartum cardiomyopathy, pulmonary 
edema associated with tocolytic therapy, and pulmonary edema 
secondary to preeclampsia-eclampsia need to be considered in 
these patients. In previous reports of patients with pulmonary 
edema associated with preeclampsia, all patients had antepartum 
evidence of preeclampsia. In this case report, we describe a case 
of early postpartum pulmonary edema in a patient with postpar-
tum preeclampsia following a relatively normal gestation and 
delivery. 
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Classified Notices 
To place a classified notice: 
HMA members.- Please send a signed and type-
written ad to the HMA office. As a benefrt of mem-
bership, HMA members may place a complimen-
tary one-time classified ad in HMJ as space is 
available. 
Nonmembers.- Please call536-n02 for a non-
member form. Rates are $1 .50 a word with a mini-
mum of 20 words or $30. Not commissionable. 
Payment must accompany written order. 
Wanted 
MD/DO wanted to join multklisciplinary personal 
injury practice. Interests in rehabilitation or internal 
medicine. Terms negotiable. Contact Dr Carl 
Gallegos at (808) 523-0030. 
Position for NYC-trained lntemlsl ER experi-
ence, ATLS/ACLS, local license and insurance. 
Aexible hrs. NY, Hawaii references. (808) 949-
6553. 
Medical Director, BEIBC FP with MPH or adminis-
trative experience preferred for rural community 
health center. Salary commensurate with experi-
ence. Call Kawahine at 259-7948 or fax 259-6449. 
Wanted! Primary care physician for fully equipped 
medical office in central Honolulu. Convenient loca-
tion. Established practice. Aexible lease or long-
term arrangement CaU 537-7 494 or 373-1824. 
Pediatrician, board-certified with 12 years solo 
practice experience desires general pediatric full or 
part time position; any area. Call524-9157 or write 
1571 Piikoi St., No 1204, Honolulu, Hl96822. 
Office Space 
Physician office space available In large medical 
group in Manoa with common clerical support. 
Available immediately. Call Ullian Evanson·Ziegler 
RN at 988-7000. 
Office space to share Kahala offiCe tower. Avail-
able now 735-7681 . 
For Sale 
For sale. Clinistat chemistry analyzer. Excellent 
condition. Reasonably priced. Contact Ana at 531-
6886. 
Active Dermatologlcel practice in fully equipped 
office for takeover. Timing and other arrangements 
very flexible. Call 528-1717 days; 732-6215 eve-
nings. 
-
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Services 
Medical billing services. Patient statements, EMC 
claims processing, accurate management reports. 
Personalized service, affordable rates. CaU Unda at 
MEDCON, 235-4782. 
Are your billing methods producing desired 
results? Pathfinder Business Services offers com-
puterized billing and accounttracking capab~ities at 
reasonable prices. Free consultation. Call 625-
1085. 
Insurance woes? Having difficulty with insurance 
collections? We have more than 15 years of insur-
ance experience. Call MEDCON, 235-4782 today! 
Medical transcriber: Independent contractor, rea-
sonable rates, 1 to 2 day turnaround, pick up and 
delivery. Reliable, professional service. Call Judy at 
593-3695. 
